Country: Malta
Language: English
Source: Medicines Authority
FINGOLIMOD
Genthon BV Microweg 22, 6545 CM NIJMEGEN, Netherlands
L04AA27
FINGOLIMOD 0.5 mg
HARD CAPSULE
FINGOLIMOD 0.5 mg
POM
IMMUNOSUPPRESSANTS
Licence number in the source country: NOT APPLICAPABLE
Withdrawn
2020-07-10
Page 1 of 12 PACKAGE LEAFLET: INFORMATION FOR THE USER FINGOLIMOD GENTHON 0.5 MG, HARD CAPSULES fingolimod READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fingolimod Genthon is and what it is used for 2. What you need to know before you take Fingolimod Genthon 3. How to take Fingolimod Genthon 4. Possible side effects 5. How to store Fingolimod Genthon 6. Contents of the pack and other information 1 WHAT FINGOLIMOD GENTHON IS AND WHAT IT IS USED FOR WHAT FINGOLIMOD GENTHON IS The active substance of Fingolimod Genthon is fingolimod. WHAT FINGOLIMOD GENTHON IS USED FOR Fingolimod Genthon is used in adults and in children and adolescents (10 years of age and above) to treat relapsing-remitting multiple sclerosis (MS), more specifically in: - Patients who have failed to respond despite treatment with an MS treatment. or - Patients who have rapidly evolving severe MS. Fingolimod Genthon does not cure MS, but it helps to reduce the number of relapses and to slow down the progression of physical disabilities due to MS. WHAT IS MULTIPLE SCLEROSIS MS is a long-term condition that affects the central nervous system (CNS), comprised of the brain and spinal cord. In MS inflammation destroys the protective sheath (called myelin) around the nerves in the CNS and stops the nerves from working properly. This is called demyelination. Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms that reflect inflammation within the CNS. Symptoms vary from patient to patient bu Read the complete document
Page 1 of 27 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fingolimod Genthon 0.5 mg, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains fingolimod hydrochloride equivalent to 0.5 mg fingolimod. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule Hard gelatine capsule of 16 mm (size 3), with a white opaque body and yellow opaque coloured cap. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Fingolimod Genthon is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older: - Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1). or - Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The treatment should be initiated and supervised by a physician experienced in multiple sclerosis. Posology In adults, the recommended dose of Fingolimod Genthon is one 0.5 mg capsule taken orally once daily. In paediatric patients (10 years of age and above), the recommended dose is dependent on body weight: - Paediatric patients with body weight <40 kg: one 0.25 mg capsule taken orally once daily. Other fingolimod-containing medicinal products are available in a lower strength (as 0.25 mg capsules) from other pharmaceutical companies. - Paediatric patients with body weight >40 kg: one 0.5 mg capsule taken orally once daily. Page 2 of 27 Paediatric patients who start on 0.25 mg capsules and subsequently reach a stable body weight above 40 kg should be switched to 0.5 mg capsules. When switching from a 0.25 Read the complete document